Compare TSCO & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSCO | UTHR |
|---|---|---|
| Founded | 1938 | 1996 |
| Country | United States | United States |
| Employees | N/A | 1400 |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 25.1B |
| IPO Year | 1996 | 1999 |
| Metric | TSCO | UTHR |
|---|---|---|
| Price | $45.03 | $571.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 14 |
| Target Price | $60.00 | ★ $561.57 |
| AVG Volume (30 Days) | ★ 5.1M | 566.2K |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.10% | N/A |
| EPS Growth | 0.98 | ★ 13.07 |
| EPS | 2.06 | ★ 27.86 |
| Revenue | ★ $15,524,046,000.00 | $1,483,300,000.00 |
| Revenue This Year | $7.30 | $7.08 |
| Revenue Next Year | $6.06 | $14.32 |
| P/E Ratio | $22.17 | ★ $20.63 |
| Revenue Growth | ★ 4.31 | 2.38 |
| 52 Week Low | $43.23 | $272.18 |
| 52 Week High | $63.99 | $607.89 |
| Indicator | TSCO | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 41.53 | 59.34 |
| Support Level | $44.44 | $464.92 |
| Resistance Level | $56.04 | $607.89 |
| Average True Range (ATR) | 1.29 | 18.54 |
| MACD | 0.21 | 0.68 |
| Stochastic Oscillator | 52.56 | 59.40 |
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,395 of its namesake banners in 49 states, along with 207 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities rather than urban and suburban areas. In fiscal 2025, revenue consisted primarily of livestock, equine & agriculture (around 30%), companion animal (25%), and seasonal & recreation (around 25%).
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.